Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies Seeks Acquisitions
Apr 23 15
Stellar Biotechnologies, Inc. (TSXV:KLH) filed a shelf registration in the amount of $100 million and will use the proceeds of the offering to in-license, acquire or invest in complementary businesses, technologies, products or assets
Stellar Biotechnologies Enters into Expanded Supply Agreement with Neovacs
Apr 14 15
Stellar Biotechnologies, Inc. and Neovacs S.A. have entered into an expanded supply agreement, under which Stellar will supply its Keyhole Limpet Hemocyanin, or KLH, for Neovacs's proprietary Kinoid immunotherapy technology. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFNalpha-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus ("lupus").
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Apr 1 15
Stellar Biotechnologies, Inc. and Neovacs S.A. announced that the companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFN?-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus. Stellar is a leader in the sustainable manufacture of KLH, an immune-stimulating protein widely used as a carrier molecule in immuno therapies under development for a variety of disease indications. Immunotherapy uses a patient's own immune system to target and treat diseases. KLH can only be produced from a scarce marine source. Stellar believes it is the only company with the proprietary technology to manage sustainable, scalable production of GMP quality KLH to meet future pharmaceutical industry demands. Neovacs is a leader in the development of active immuno therapies for the treatment of chronic autoimmune diseases. Neovacs' patented Kinoid technology combines a select cytokine of interest attached to KLH as the immune-stimulating carrier protein. The resulting immunotherapy uses the patient's immune system to generate antibodies against the targeted disease. This phase IIb study is expected to begin mid-2015. A U.S. Phase IIa trial of IFN-Kinoid for the treatment of lupus in the U.S. is expected to commence by early 2016. Under the terms of the agreement, Neovacs will purchase Stellar KLH for use in its proprietary KLH-based Kinoid immunotherapies in the European Union, Latin America, Asia, the U.S. and Canada. Neovacs will use Stellar KLH for its planned Phase II and Phase III clinical trials and for expected commercial manufacturing of its products for up to one year following market approval. Neovacs will manage and fund all product development and regulatory submissions for its immunotherapy products and act as the sponsor company for the future clinical trials. Stellar will supply GMP grade KLH to Neovacs according to agreed specifications, quantities, and pricing, as well as maintain a master file with the U.S. FDA for the KLH product. Stellar will also provide professional, technical, and regulatory support to Neovacs. The agreement has an initial five-year term, which may be renewed by Neovacs in one-year increments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|